Search results for "Peak oxygen consumption"

showing 2 items of 2 documents

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chro…

2016

Inflammatory activation plays a pivotal role in chronic heart failure (CHF) through the increased expression of pro-inflammatory cytokines [1]. Decreased plasma levels of Interleukin (IL-) 5, IL-7 and Interferon-γ (IFN-γ) and increased levels of IL-9 have been already described in CHF [2], and a negative correlation was also reported between IL-9 and left ventricular ejection fraction (LVEF) [2]. Yet, there are only limited data exploring the association between cytokines and functional capacity in CHF and their prognostic role [3]; therefore, primary end-point of the current study was to evaluate all-cause mortality according to changes in cytokines plasma levels in CHF patients.  

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathmedicineHumansInterleukin 9030212 general & internal medicineInterleukin 6CytokineInterleukin 5Risk stratificationInterleukin 4OutcomeAgedHeart Failurebiologybusiness.industryRisk FactorInterleukin-9Middle Agedmedicine.diseaseChronic heart failurePeak oxygen consumptionInterleukin 10EndocrinologyInterleukin 15Heart failurebiology.proteinCardiologyFemaleChronic heart failure; Cytokines; Interleukin-9; Outcomes; Peak oxygen consumption; Risk stratification; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular MedicinebusinessInterleukin 1 receptor type IHumanInternational journal of cardiology
researchProduct

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction

2020

Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mortality in patients with cardiovascular disease. Sacubitril/valsartan (S/V) is a treatment for heart failure with reduced ejection fraction (HFrEF), which impressively impacts cardiovascular outcome. This study aims at evaluating the effects of S/V on HRR and its correlation with cardiopulmonary indexes in HFrEF patients. Methods: Patients with HFrEF admitted to outpatients&rsquo

medicine.medical_specialtyStress testingheart failurelcsh:Medicinecardiopulmonary exercise stress testing030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciencessacubitril/valsartan heart failure heart rate recovery peak oxygen consumption autonomic function cardiopulmonary exercise stress testing0302 clinical medicineInternal medicineHeart ratemedicine030212 general & internal medicinepeak oxygen consumptionheart rate recoveryEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseValsartansacubitril/valsartanHeart failureBreathingCardiologyautonomic functionbusinesshuman activitiesSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct